Lyka Labs Limited

Lyka Labs Limited, established on December 29, 1976, is a prominent Indian pharmaceutical company specializing in the development, manufacturing, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company is headquartered in Mumbai, Maharashtra, India, at Spencer Building, Ground Floor, 30 Forjett Street, Tardeo, Grant Road West, Mumbai 400036. The Corporate Identification Number (CIN) assigned to Lyka Labs Limited is L24230GJ1976PLC008738. As of the latest available data, the company employs approximately 499 individuals. Lyka Labs Limited is publicly listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE), with the ticker symbol 500259 on BSE and LYKALABS on NSE. The company's official website is www.lykalabs.com.

Lyka Labs Limited operates a WHO-GMP certified and ISO 9001:2000 certified manufacturing facility located in Ankleshwar, Gujarat, India. This facility specializes in the production of a diverse range of pharmaceutical formulations, including lyophilized injections, topical formulations such as creams, ointments, foams, gels, and lotions. The manufacturing plant is equipped with state-of-the-art infrastructure to ensure the consistent quality and reliability of its products.

The leadership team at Lyka Labs Limited comprises several key executives:

• Kunal Narendra Gandhi: Managing Director, Chief Executive Officer, Promoter, and Director.

• Yogesh Babulal Shah: Chief Financial Officer and Executive Director.

• Shailendra Kumar Agrawal CS: Company Secretary and Compliance Officer.

• Babulal Jain: Independent Director.

• Prashant Premchand Godha: Non-Executive Director.

• Shashil Philip Mendonsa: Non-Executive Director.

• Neeraj Golas: Independent Director.

Lyka Labs Limited has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Ankleshwar, Gujarat, holds WHO-GMP and ISO 9001:2000 certifications, which are essential for market access in these regions. While specific details regarding regulatory filings, approvals, and market access status in these countries are not publicly disclosed, the company's adherence to international quality standards positions it favorably for entry into these markets.

Lyka Labs Limited has demonstrated a commitment to expanding its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's WHO-GMP and ISO 9001:2000 certifications enhance its credibility and facilitate access to these regions. Additionally, the company's export activities, as evidenced by its total export value of $3.4 million USD and 104 shipments across five therapeutic categories, indicate a proactive approach to penetrating diverse markets.

Lyka Labs Limited's geographic strategy appears to be focused on diversification, as evidenced by its export activities across multiple therapeutic categories and regions. The company's portfolio concentration, with the top five products accounting for 100% of its export value, suggests a strategic emphasis on a select range of products. This approach may mitigate risks associated with over-reliance on a single product or market. However, the lack of a market leader position in any specific category indicates potential opportunities for growth and increased market share.

Specific details regarding Lyka Labs Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's adherence to WHO-GMP and ISO 9001:2000 certifications suggests a commitment to quality standards that align with FDA requirements. However, without explicit FDA approvals or registrations, the company's products may face challenges in entering the U.S. market.

Lyka Labs Limited's manufacturing facility holds WHO-GMP and ISO 9001:2000 certifications, indicating compliance with international quality standards. While these certifications are recognized globally, including in the European Union, specific EU GMP certificates or EDQM status are not publicly disclosed. Obtaining EU GMP certification would be advantageous for market access within the European Union.

Lyka Labs Limited's manufacturing facility is licensed by the Central Drugs Standard Control Organisation (CDSCO), as evidenced by its WHO-GMP and ISO 9001:2000 certifications. The company also holds state drug controller approvals and export No Objection Certificates (NOCs), facilitating its export activities. These regulatory approvals underscore the company's compliance with Indian pharmaceutical regulations and its commitment to quality standards.

As of the latest available information, there are no publicly disclosed Form 483 observations, warning letters, or import alerts associated with Lyka Labs Limited. The company's adherence to WHO-GMP and ISO 9001:2000 certifications suggests a proactive approach to maintaining compliance with international quality standards.

Lyka Labs Limited operates in a competitive pharmaceutical industry, with numerous companies offering similar products across overlapping therapeutic categories. While specific market share comparisons and head-to-head analyses are not publicly available, the company's export activities, including a total export value of $3.4 million USD and 104 shipments across five therapeutic categories, indicate a proactive approach to market penetration. The lack of a market leader position in any specific category suggests opportunities for growth and increased market share.

Lyka Labs Limited's key differentiators include its commitment to innovation, as evidenced by its state-of-the-art manufacturing facility and adherence to international quality standards. The company's focus on a select range of products, with the top five products accounting for 100% of its export value, indicates a strategic emphasis on quality and reliability. Additionally, the company's proactive approach to export activities demonstrates its commitment to expanding its global footprint.

Lyka Labs Limited's current strategic direction appears to be focused on the development and export of a select range of pharmaceutical formulations, with an emphasis on quality and reliability. The company's adherence to WHO-GMP and ISO 9001:2000 certifications underscores its commitment to international quality standards. Future outlooks may include expanding its product portfolio, obtaining additional regulatory approvals, and increasing market share in both existing and new markets.

Lyka Labs Limited has demonstrated a consistent track record in manufacturing and exporting pharmaceutical formulations, with a total export value of $3.4 million USD and 104 shipments across five therapeutic categories. The company's adherence to WHO-GMP and ISO 9001:2000 certifications indicates a commitment to quality and reliability. However, the lack of specific FDA approvals or registrations may impact its ability to supply certain markets, such as the United States.

Importers should verify the following certifications when considering Lyka Labs Limited as a supplier:

• WHO-GMP Certification: Indicates compliance with World Health Organization Good Manufacturing Practices.

• ISO 9001:2000 Certification: Demonstrates adherence to international quality management standards.

These certifications can typically be verified through the company's official website or by contacting the company directly.

When conducting due diligence on Lyka Labs Limited, consider the following steps:

• Verify Certifications: Confirm the validity of WHO-GMP and ISO 9001:2000 certifications.

• Assess Regulatory Approvals: Determine the company's compliance with relevant regulatory bodies in target markets.

• Evaluate Financial Performance: